Browse by Poster Presenter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Browse by Poster Presenter

Type here to filter the list

A
Agarwal, Palak

University of Southern California
(W1130-02-08) Oral Absorption of Semaglutide: Pharmacokinetic Modeling and Molecular Dynamics Simulations
Palak Agarwal
Favorite
Aguilera, J. Javier

Moderna Therapeutics
(T1530-02-06) Development of an Electrochemiluminescent Assay for the Detection of Anti-PEG IgE Antibodies in Human Serum
J. Javier Aguilera
Favorite
Ahmad, Javed

Najran University
(W1030-01-02) Potential Biomedical Applications of Silver Nanoparticles Synthesized Using Anisotes trisulcus Extract from Saudi Arabia: Antioxidant, Antibacterial, and Anti-Proliferative Properties
Javed Ahmad
Favorite
Ahmad, Mohammad Zaki

Najran University
(W1030-01-02) Potential Biomedical Applications of Silver Nanoparticles Synthesized Using Anisotes trisulcus Extract from Saudi Arabia: Antioxidant, Antibacterial, and Anti-Proliferative Properties
Mohammad Zaki Ahmad
Favorite
Ahsan, Fakhrul

California Northstate University
(W1030-01-04) Preparation and Scale-Up of Liposomal Amphotericin B Formulation and a Comparison with Commercially Available Counterpart, Ambisome®
Fakhrul Ahsan
Favorite
Akkbik, Mohammed

Qatar University
(W1330-01-04) Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Mohammed Akkbik
Favorite
Alany, Raid

Kingston University London
(W1330-01-04) Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Raid Alany
Favorite
Ali Adib, Sandi

Qatar University
(W1330-01-04) Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Sandi Ali Adib
Favorite
Al-Kinani, Ali

Kingston University London
(W1330-01-04) Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Ali Al-Kinani
Favorite
Allen, Scott

BioAgilityx Labs
(W1230-02-10) Qualification of a 48-plex Cytokine Olink Panel to Support Rare Disease and Pediatric Clinical Studies
Scott Allen
Favorite
Allison, Jason

Yokogawa Fluence Analytics
(T1430-01-01) Static Light Scattering Signatures Used to Identify and Minimize Aggregation During Formulation Development
Jason Allison
Favorite
Alqahtani, Abdulsalam A.

Najran University
(W1030-01-02) Potential Biomedical Applications of Silver Nanoparticles Synthesized Using Anisotes trisulcus Extract from Saudi Arabia: Antioxidant, Antibacterial, and Anti-Proliferative Properties
Abdulsalam A. Alqahtani
Favorite
Al-Qahtani, Noora

Qatar University
(W1330-01-04) Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Noora Al-Qahtani
Favorite
Amiji, Mansoor

Northeastern University
(W1330-01-05) Extrapolating the Use of Microfluidic Chips to Formulate Reproducible and Effective Nanoemulsions for Subunit Vaccines: A Paradigm Shift in Manufacturing Emulsion Adjuvants
Mansoor Amiji
Favorite
Anastasiou, Imogen

Pion Inc.
(T1030-01-02) Demonstrating the Excipient Effect In Vitro for Pre-clinical Formulation Analysis
Imogen Anastasiou
Favorite
Andrews, Benjamin

Biopharmaceutical Research Inc.
(T1330-02-08) Production and Characterization of Critical Biotin and DIG Conjugated RESCA-Anti-CD8 VHH Reagents to Enable the Non-Clinical and Clinical Anti-Drug Antibody Assay Development
Benjamin Andrews
Favorite
Arjomandi, Audrey

Genentech, Inc.
(T1330-02-06) Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Audrey Arjomandi
Favorite
Awasthi, Shivangi

Merck Sharp & Dohme Corp.
(W1330-02-07) Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Shivangi Awasthi
Favorite
Azumai, Satomi

Daiichi Sankyo Co., Ltd.
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Satomi Azumai
Favorite
(W1230-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Satomi Azumai
Favorite
B
Baghla, Rahul

SCIEX
(T1430-02-07) Analysis of Glucagon-Like Peptide-1 (GLP-1) Analog in Rat Plasma Using an LC-MS/MS Workflow
Rahul Baghla
Favorite
Banga, Ajay

Mercer University
(T1430-01-02) Enhanced Transdermal Delivery of Anticancer Agent: A Comprehensive Study on Fractional Ablative Laser
Ajay Banga
Favorite
Bano, Nazneen

Merck Sharp & Dohme Corp.
(W1330-02-07) Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Nazneen Bano
Favorite
Barnwal, Ravi

Panjab University
(W1230-02-07) Docetaxel and QDs Based Nano Lipidic Theragnostic System for Cure and Real-Time Monitoring of Breast Cancer: Efficacy and Safety Studies in Rats
Ravi Barnwal
Favorite
Bengson, Yingjia

Ultragenyx Pharmaceuticals
(W1430-02-10) Analysis of Anti-Drug Antibodies (ADA) in Multiple Animal Species from mRNA LNP Therapeutics Supporting Rare Diseases Demonstrated Low Immunogenicity of PEG-2000 by ECLA and ELISA Methodology
Yingjia Bengson
Favorite
Bergström, Christel

Uppsala University
(W1030-02-08) Optimization of Artificial Colonic Mucus for Drug Diffusion Study
Christel Bergström
Favorite
Berry, Deborah L.

AstraZeneca
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Deborah L. Berry
Favorite
Bhangde, Shashank

Northeastern University
(W1330-01-05) Extrapolating the Use of Microfluidic Chips to Formulate Reproducible and Effective Nanoemulsions for Subunit Vaccines: A Paradigm Shift in Manufacturing Emulsion Adjuvants
Shashank Bhangde
Favorite
Bhatia, Alka

Post Graduate Institute of Medical Education and Research
(W1230-02-07) Docetaxel and QDs Based Nano Lipidic Theragnostic System for Cure and Real-Time Monitoring of Breast Cancer: Efficacy and Safety Studies in Rats
Alka Bhatia
Favorite
Bigos, Pawel

Waters Corporation
(W1330-02-10) Next-Generation Biocompatible HPLC System for Enhanced Analysis of Biotherapeutics
Pawel Bigos
Favorite
Biibosunov, Aidin

Differentia Bio
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Aidin Biibosunov
Favorite
Birdsall, Robert

Waters Corporation
(W1330-02-10) Next-Generation Biocompatible HPLC System for Enhanced Analysis of Biotherapeutics
Robert Birdsall
Favorite
Blanco, Veronica

Croda, Inc.
(T1330-01-05) Optimizing Lipid Nanoparticles (LNPs) Processing for siRNA Delivery by Microfluidics System
Veronica Blanco
Favorite
Bobbala, Sharan

West Virginia University
(T1030-01-05) Flash Nanoprecipitation Permits Self-assembly of Ionizable Lipid Nanoparticles for Nucleic Acid Delivery
Sharan Bobbala
Favorite
(T1430-01-04) Ionizable Lipid Nanoparticles for Dual siRNA/Chemotherapy Delivery for B-cell ALL Treatment
Sharan Bobbala
Favorite
Bose, Sarbamangala

University of Bradford
(T1030-02-08) Single Cell Gel Electrophoresis to Detect Genotoxicity of Iminostilbene, a Process Induced Impurity of Carbamazepine
Sarbamangala Bose
Favorite
Boswell, Andy

Genentech, Inc.
(T1030-02-09) Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Andy Boswell
Favorite
Bounkhoun, Dominic

Janssen Research & Development, LLC
(T1130-02-09) Evaluation of Sample Preparation Techniques for Protein Quantification
Dominic Bounkhoun
Favorite
Bovin, Lone Frier

Svar Life Science AB
(W1130-02-11) Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Lone Frier Bovin
Favorite
Bowsher, Ron

B2S Life Sciences
(W1430-02-06) Application of a Novel Affinity Purified Chicken IgY in an Immunoaffinity LC-MS/MS Assay for Rapid Quantitation of Monoclonal Antibody Therapeutics and ADCs in Nonclinical Species
Ron Bowsher
Favorite
Boylan, Nicholas

Phosphorex
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Nicholas Boylan
Favorite
Boyle, Christine

EpiVax, Inc.
(W1230-02-11) Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
Christine Boyle
Favorite
Bretton, Vera

Prolytix
(T1030-02-07) Analytical Method Validation Strategy for Determination of Charge Heterogeneity of Antibody Therapeutics Using Reference Material Comparison as an Alternative to Spiking Studies
Vera Bretton
Favorite
Brumm, Jochen

Genentech, Inc.
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Jochen Brumm
Favorite
C
Cahayag, Rhea

Ultragenyx Pharmaceuticals
(W1430-02-10) Analysis of Anti-Drug Antibodies (ADA) in Multiple Animal Species from mRNA LNP Therapeutics Supporting Rare Diseases Demonstrated Low Immunogenicity of PEG-2000 by ECLA and ELISA Methodology
Rhea Cahayag
Favorite
Calderon, Chris

Ursa Analytics
(T1330-01-03) Stain-Free Approach to Determine and Monitor Cell Heath Using Supervised and Unsupervised Image-Based Deep Learning
Chris Calderon
Favorite
(W1030-02-11) Machine Learning Approaches to Analysis of Microscopy Images of Polysorbate Degradation Product Particles
Chris Calderon
Favorite
Celik, Selvi

Svar Life Science AB
(W1130-02-11) Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Selvi Celik
Favorite
Centola, Garrick

US Food and Drug Administration
(W1030-02-07) Comparative Analyses of Thermal Stability Amplifying Peptide Dendrons and Polysorbates
Garrick Centola
Favorite
Chakrapeesirisuk, Nopdanai

Uppsala University
(W1030-02-08) Optimization of Artificial Colonic Mucus for Drug Diffusion Study
Nopdanai Chakrapeesirisuk
Favorite
Chang, Su-youne

Mayo Clinic
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Su-youne Chang
Favorite
Chang, Ying-Chih

Acrocyte
(W1430-02-08) In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Ying-Chih Chang
Favorite
Chan, Phyllis

Genentech, Inc.
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Phyllis Chan
Favorite
(T1430-02-09) Bridging Bevacizumab PK from Adults to Pediatrics through PBPK Modeling
Phyllis Chan
Favorite
Chanu, Pascal

Genentech, Inc.
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Pascal Chanu
Favorite
Chappell, John

Gyros Protein Technologies
(T1330-02-11) Oligonucleotide Dual Hybridization Assay Using Offline Pre-incubation followed by an Automated Microfluidic Method
John Chappell
Favorite
(T1530-02-10) Development of a Generic, Automated, Microfluidic Human IgG-FcRn Affinity Assay In-Solution for Use in Antibody Engineering
John Chappell
Favorite
Chavez, Alfonso

NeuroOne
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Alfonso Chavez
Favorite
Chengalvala, Murty

LabCorp
(W1230-01-05) Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Murty Chengalvala
Favorite
Chen, Hsin

Janssen Research & Development, LLC
(T1130-02-09) Evaluation of Sample Preparation Techniques for Protein Quantification
Hsin Chen
Favorite
Chen, Ming-Luan

Altasciences
(T1230-02-11) Sensitive Quantitation of Antisense Oligonucleotides Using Capitainer^® qDBS Microsampling Device Coupled with Hybridization LC-MS/MS
Ming-Luan Chen
Favorite
Chen, Weixuan

Janssen Research & Development, LLC
(T1130-02-09) Evaluation of Sample Preparation Techniques for Protein Quantification
Weixuan Chen
Favorite
Chen, Zhongying

Astrazeneca
(W1130-02-07) Biodistribution Study of a Bivalent SARS-CoV-2 mRNA Vaccine in Rat
Zhongying Chen
Favorite
Chiu, Tim

Ultragenyx Pharmaceuticals
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC^spf-ash Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Tim Chiu
Favorite
Cho, Nick

Genentech, Inc.
(T1030-02-09) Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Nick Cho
Favorite
Coble, Kelly

Boehringer Ingelheim
(T1230-02-07) A Validated Immunocapture LC-MS/MS Hybrid Assay for the Quantitation of a Novel Multi-Domain Therapeutic Protein in Human Plasma with Clinical Sample Analysis
Kelly Coble
Favorite
Coleman, Holly

University of Colorado Boulder
(W1330-01-01) Stabilization of Viruses for Vaccines and Gene Therapy by Spray Drying and Lyophilization
Holly Coleman
Favorite
Contrepois, Kévin

AstraZeneca
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Kévin Contrepois
Favorite
Cookson, Colt

Veloxity Labs
(W1430-02-06) Application of a Novel Affinity Purified Chicken IgY in an Immunoaffinity LC-MS/MS Assay for Rapid Quantitation of Monoclonal Antibody Therapeutics and ADCs in Nonclinical Species
Colt Cookson
Favorite
Cornish, Georgina

AstraZeneca
(T1130-02-06) Biodistribution Analysis of GPC-3 CAR-T Cells in NSG Mice by a Universal ddPCR Assay to Support an IND-Enabling Toxicity Study
Georgina Cornish
Favorite
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Georgina Cornish
Favorite
Crul, Mirjam

Amsterdam University Medical Center
(T1030-01-03) Stability of Therapeutic Monoclonal Antibodies during Infusion with Elastomeric Pumps Intended for Home-Based Therapy
Mirjam Crul
Favorite
Cueto, Maria

Merck & Co., Inc.
(T1230-01-01) Parallel-Competitive Absorption Metabolism Model for Calculation of Subcutaneous Bioavailability of Monoclonal Antibodies
Maria Cueto
Favorite
D
Davanidavari, Dorna

Chapman University
(W1030-02-09) Design and Evaluation of a Cyclic Peptide-Epirubicin Conjugate to Enhance Anticancer Activity and Reduce Cardiac Toxicity
Dorna Davanidavari
Favorite
Davies, John

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
John Davies
Favorite
Davis, Don

Janssen Research & Development, LLC
(T1130-02-09) Evaluation of Sample Preparation Techniques for Protein Quantification
Don Davis
Favorite
DeGroot, Anne

EpiVax, Inc.
(T1130-02-11) Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Anne DeGroot
Favorite
(W1130-02-09) Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
Anne DeGroot
Favorite
(W1230-02-11) Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
Anne DeGroot
Favorite
de Leeuw, Erik

LabCorp
(W1230-01-05) Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Erik de Leeuw
Favorite
DeGroot, Anne

EpiVax, Inc.
(W1530-02-10) An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)
Anne DeGroot
Favorite
Del Rosario, Geoffrey

Genentech, Inc.
(T1030-02-09) Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Geoffrey Del Rosario
Favorite
DelCarpini, Jason

Moderna Therapeutics
(T1530-02-06) Development of an Electrochemiluminescent Assay for the Detection of Anti-PEG IgE Antibodies in Human Serum
Jason DelCarpini
Favorite
Deng, Bijia

Wave Life Sciences
(W1230-02-06) Strategies for the Development and Characterization of Sensitive Anti-oligonucleotide Antibodies for Application in Anti-drug Antibody Assays
Bijia Deng
Favorite
DeSilva, Binodh

Ultragenyx Pharmaceuticals
(W1430-02-10) Analysis of Anti-Drug Antibodies (ADA) in Multiple Animal Species from mRNA LNP Therapeutics Supporting Rare Diseases Demonstrated Low Immunogenicity of PEG-2000 by ECLA and ELISA Methodology
Binodh DeSilva
Favorite
Dhungana, Suraj

Waters Corporation
(W1330-02-10) Next-Generation Biocompatible HPLC System for Enhanced Analysis of Biotherapeutics
Suraj Dhungana
Favorite
Diaz-Botia, Camilo

NeuroOne
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Camilo Diaz-Botia
Favorite
Ding, Ling

University of Nebraska Medical Center
(T1230-01-05) Development of Inhalable Polymeric Nanoemulsions for Delivery of Gene Silencing Therapeutics in Lung Tumors
Ling Ding
Favorite
Dockrey, Summer

Genentech, Inc.
(T1030-02-09) Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Summer Dockrey
Favorite
Dragovich, Peter

Genentech, Inc.
(T1030-02-09) Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Peter Dragovich
Favorite
Druschitz, Amy

Croda, Inc.
(T1330-01-05) Optimizing Lipid Nanoparticles (LNPs) Processing for siRNA Delivery by Microfluidics System
Amy Druschitz
Favorite
Dubey, Sheri

Merck Sharp & Dohme Corp.
(W1330-02-11) One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Sheri Dubey
Favorite
Duong-Ly, Krisna

Merck & Co., Inc.
(T1530-02-09) False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Krisna Duong-Ly
Favorite
Du, Xiangsha

Waters Corporation
(W1330-02-10) Next-Generation Biocompatible HPLC System for Enhanced Analysis of Biotherapeutics
Xiangsha Du
Favorite
E
Eacret, Jacqueline

Merck & Co., Inc.
(W1330-02-11) One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Jacqueline Eacret
Favorite
Eades, William

University of Cincinnati
(W1030-01-03) Oral Delivery of Remdesivir Analogues: Alternatives for Intravenous Remdesivir with Reduced Potential Drug-Drug Interactions
William Eades
Favorite
Eckerston, Ann

Gyros Protein Technologies
(T1530-02-10) Development of a Generic, Automated, Microfluidic Human IgG-FcRn Affinity Assay In-Solution for Use in Antibody Engineering
Ann Eckerston
Favorite
Edman, Maria

University of Southern California
(W1230-01-03) Elastin-Like Polypeptide (ELP) Antibody Fusions Targeting IL-6: Pharmacology and Pharmacokinetics
Maria Edman
Favorite
Elkins, Stephanie

EpiVax, Inc.
(T1130-02-11) Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Stephanie Elkins
Favorite
(W1530-02-10) An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)
Stephanie Elkins
Favorite
Elliott, Rebecca

Genentech, Inc.
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Rebecca Elliott
Favorite
Eriksson, Jens

Uppsala University
(W1030-02-08) Optimization of Artificial Colonic Mucus for Drug Diffusion Study
Jens Eriksson
Favorite
Esen, Emel

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Emel Esen
Favorite
Evans, Jason

Q Squared Solutions
(W1430-02-09) Exploring the Future Potentials of High-Resolution Mass Spectrometry for Regulated Bioanalysis
Jason Evans
Favorite
F
Farrell, Jaymes

BioAgilytix Labs
(W1230-02-10) Qualification of a 48-plex Cytokine Olink Panel to Support Rare Disease and Pediatric Clinical Studies
Jaymes Farrell
Favorite
Finn, M.G.

Georgia Institute of Technology
(W1330-01-03) Deciphering the Role of Hydrogel Network Topology in Programmably Degradable Hydrogels
M.G. Finn
Favorite
Fischer, Saloumeh

Genentech, Inc.
(T1330-02-09) Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Saloumeh Fischer
Favorite
(W1130-02-10) Choosing the Right Bioanalytical Platform to Accommodate a Biotherapeutic Pharmacokinetic Measurement in Serum and CSF: A Case Study
Saloumeh Fischer
Favorite
Fisher, Brianna

NanoImaging Services
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Brianna Fisher
Favorite
Flagella, Kelly

Ultragenyx Pharmaceuticals
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC^spf-ash Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Kelly Flagella
Favorite
Fong, Karen

NanoImaging Services
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Karen Fong
Favorite
Furlan, Alicia

Correlia
(T1330-02-10) Novel Immunoassay Technology: Evaluating the PIXI Platform for Rapid Quantitation with Automation, Wide Dynamic Range, and Small Sample Volume Requirement
Alicia Furlan
Favorite
G
Gampa, Gautham

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Gautham Gampa
Favorite
Gao, Hui

Peking University International Hospital
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Hui Gao
Favorite
Garcea, Robert

University of ColoradoBoulder
(W1330-01-01) Stabilization of Viruses for Vaccines and Gene Therapy by Spray Drying and Lyophilization
Robert Garcea
Favorite
Garliyev, Victor

Merck & Co., Inc.
(W1330-02-11) One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Victor Garliyev
Favorite
Getz, Jennifer

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Jennifer Getz
Favorite
Ge, Yan

AliveX Biotech
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Yan Ge
Favorite
Ghomlaghi, Milad

AliveX Biotech
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Milad Ghomlaghi
Favorite
Giamouridis, Dimosthenis

Charles River Laboratories
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC^spf-ash Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Dimosthenis Giamouridis
Favorite
Gianneli, Maria

Gyros Protein Technologies
(W1130-02-11) Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Maria Gianneli
Favorite
Gomes, Conor

Pion Inc.
(T1030-01-02) Demonstrating the Excipient Effect In Vitro for Pre-clinical Formulation Analysis
Conor Gomes
Favorite
Gomez, Andrea

Merck & Co., Inc.
(T1030-02-11) The Importance of Orthogonal Methods for the Determination of the Size Distribution of Lipid Nanoparticles
Andrea Gomez
Favorite
Gomibuchi, Mami

Eisai Co., Ltd.
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Mami Gomibuchi
Favorite
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Mami Gomibuchi
Favorite
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Mami Gomibuchi
Favorite
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Mami Gomibuchi
Favorite
Gopalan, Rajendran

University of Bradford
(T1030-02-08) Single Cell Gel Electrophoresis to Detect Genotoxicity of Iminostilbene, a Process Induced Impurity of Carbamazepine
Rajendran Gopalan
Favorite
Gosselin, Nathalie

Certara
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Nathalie Gosselin
Favorite
Greenblott, David

University of Colorado Boulder
(W1030-02-11) Machine Learning Approaches to Analysis of Microscopy Images of Polysorbate Degradation Product Particles
David Greenblott
Favorite
Guelman, Sebastian

Genentech, Inc.
(T1230-02-10) Development of a Highly Sensitive Immunoassay to Measure Circulating Levels of a Nanobody-Based Imaging Agent
Sebastian Guelman
Favorite
Gupta, Manju

Ultragenyx Pharmaceuticals
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC^spf-ash Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Manju Gupta
Favorite
Gutierrez, Andres

EpiVax, Inc.
(T1130-02-11) Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Andres Gutierrez
Favorite
H
Haegele, Joseph

Wave Life Sciences
(W1230-02-06) Strategies for the Development and Characterization of Sensitive Anti-oligonucleotide Antibodies for Application in Anti-drug Antibody Assays
Joseph Haegele
Favorite
Halpern, Wendy

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Wendy Halpern
Favorite
Haltaufderhyde, Kirk

EpiVax, Inc.
(W1230-02-11) Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
Kirk Haltaufderhyde
Favorite
Hamm-Alvarez, Sarah

University of Southern California
(W1230-01-03) Elastin-Like Polypeptide (ELP) Antibody Fusions Targeting IL-6: Pharmacology and Pharmacokinetics
Sarah Hamm-Alvarez
Favorite
Han, Yi-Chun

Cellentia, Inc.
(W1430-02-08) In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Yi-Chun Han
Favorite
Haridas, V

Indian Institute of Technology
(W1030-02-07) Comparative Analyses of Thermal Stability Amplifying Peptide Dendrons and Polysorbates
V Haridas
Favorite
Hasebe, Takashi

Eisai Co., Ltd.
(T1330-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Takashi Hasebe
Favorite
Haworth, Ian

University of Southern California
(W1130-02-08) Oral Absorption of Semaglutide: Pharmacokinetic Modeling and Molecular Dynamics Simulations
Ian Haworth
Favorite
Hedström, Kira

Gyros Protein Technologies
(W1130-02-11) Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Kira Hedström
Favorite
Hendricks, Robert

Genentech, Inc.
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Robert Hendricks
Favorite
Hernandez-Barry, Hilda

Genentech, Inc.
(T1030-02-09) Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Hilda Hernandez-Barry
Favorite
Herraez-Baranda, Luis

F. Hoffmann-La Roche Ltd.
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Luis Herraez-Baranda
Favorite
Hirokawa, Mai

Mitsubishi Tanabe Pharma Corporation
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Mai Hirokawa
Favorite
(W1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides III Thermodynamic Analysis on Higher-Order Structure of Oligonucleotides
Mai Hirokawa
Favorite
Ho, Jason

Genentech, Inc.
(T1030-02-09) Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Jason Ho
Favorite
Homan, Ying

Merck & Co., Inc.
(W1330-02-11) One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Ying Homan
Favorite
Hoover, Clare

AstraZeneca
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Clare Hoover
Favorite
Hoover, Gillian

LabCorp
(W1230-01-05) Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Gillian Hoover
Favorite
Horst, Sarah

LabCorp
(W1230-01-05) Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Sarah Horst
Favorite
Hosseini, Iraj

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Iraj Hosseini
Favorite
Hou, Xiaoqiang

AliveX Biotech
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Xiaoqiang Hou
Favorite
Hsieh, SuChun

Merck & Co., Inc.
(T1230-02-08) Quantitation of Soluble Tumor-Associated Antigens (sTAA) in Tumor Interstitial Fluid (TIF) Isolated from Frozen Solid Tumors
SuChun Hsieh
Favorite
Hsu, Jing-Ya

National Taiwan University
(W1030-02-10) Delivery of Carbonic Anhydrase 9 siRNA by Lipid Nanoparticles
Jing-Ya Hsu
Favorite
Huang, Catherine

Genentech, Inc.
(T1230-02-10) Development of a Highly Sensitive Immunoassay to Measure Circulating Levels of a Nanobody-Based Imaging Agent
Catherine Huang
Favorite
Huang, Lichun

Cellentia, Inc.
(T1330-02-10) Novel Immunoassay Technology: Evaluating the PIXI Platform for Rapid Quantitation with Automation, Wide Dynamic Range, and Small Sample Volume Requirement
Lichun Huang
Favorite
Huang, Weize

Genentech, Inc.
(T1430-02-09) Bridging Bevacizumab PK from Adults to Pediatrics through PBPK Modeling
Weize Huang
Favorite
Huffnagle, Ian

Merck & Co., Inc.
(T1530-02-09) False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Ian Huffnagle
Favorite
Hughes, Krystal

West Virginia University
(T1430-01-04) Ionizable Lipid Nanoparticles for Dual siRNA/Chemotherapy Delivery for B-cell ALL Treatment
Krystal Hughes
Favorite
Hu, Qiaobin

Croda, Inc.
(T1330-01-05) Optimizing Lipid Nanoparticles (LNPs) Processing for siRNA Delivery by Microfluidics System
Qiaobin Hu
Favorite
Huseni, Mahrukh

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Mahrukh Huseni
Favorite
I
Ikemoto, Keisuke

Mitsubishi Tanabe Pharma Corporation
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Keisuke Ikemoto
Favorite
(W1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides III Thermodynamic Analysis on Higher-Order Structure of Oligonucleotides
Keisuke Ikemoto
Favorite
J
Jacobson, Magdalena

Swedish University of Agricultural Sciences
(W1030-02-08) Optimization of Artificial Colonic Mucus for Drug Diffusion Study
Magdalena Jacobson
Favorite
Jain, Ashvi

University of Pennsylvania
(W1330-02-11) One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Ashvi Jain
Favorite
Jainul Abdeen, Sanofar

B2S Life Sciences
(W1430-02-06) Application of a Novel Affinity Purified Chicken IgY in an Immunoaffinity LC-MS/MS Assay for Rapid Quantitation of Monoclonal Antibody Therapeutics and ADCs in Nonclinical Species
Sanofar Jainul Abdeen
Favorite
Janssen, Mandy

NanoImaging Services
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Mandy Janssen
Favorite
Jogdeo, Chinmay

University of Nebraska Medical Center
(T1230-01-05) Development of Inhalable Polymeric Nanoemulsions for Delivery of Gene Silencing Therapeutics in Lung Tumors
Chinmay Jogdeo
Favorite
Johnson, Mitch

Veloxity Labs
(W1430-02-06) Application of a Novel Affinity Purified Chicken IgY in an Immunoaffinity LC-MS/MS Assay for Rapid Quantitation of Monoclonal Antibody Therapeutics and ADCs in Nonclinical Species
Mitch Johnson
Favorite
K
Kaar, Joel

University of Colorado Boulder
(W1330-01-01) Stabilization of Viruses for Vaccines and Gene Therapy by Spray Drying and Lyophilization
Joel Kaar
Favorite
Kadavil, Hana

Qatar University
(W1330-01-04) Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Hana Kadavil
Favorite
Kamath, Amrita

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Amrita Kamath
Favorite
(T1430-02-08) Leveraging Buprenorphine as a Tool Molecule to Develop a Novel PBPK Model Accounting for Intestinal Lymphatic Absorption
Amrita Kamath
Favorite
(T1530-02-07) Integrated HypoSkin® Model and PBPK Modeling as a Bioavailability Predicting Tool for Subcutaneous Delivery of Protein Therapeutics
Amrita Kamath
Favorite
Kapoor, Yash

Merck & Co., Inc.
(T1230-01-01) Parallel-Competitive Absorption Metabolism Model for Calculation of Subcutaneous Bioavailability of Monoclonal Antibodies
Yash Kapoor
Favorite
Kassir, Nastya

Genentech, Inc.
(T1430-02-09) Bridging Bevacizumab PK from Adults to Pediatrics through PBPK Modeling
Nastya Kassir
Favorite
Kathenes, Alexandra

AstraZeneca
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Alexandra Kathenes
Favorite
Katsura, Shinji

Taiho Pharmaceutical Co., Ltd.
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Shinji Katsura
Favorite
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Shinji Katsura
Favorite
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Shinji Katsura
Favorite
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Shinji Katsura
Favorite
Kaur, Indu Pal

Panjab University
(W1230-02-07) Docetaxel and QDs Based Nano Lipidic Theragnostic System for Cure and Real-Time Monitoring of Breast Cancer: Efficacy and Safety Studies in Rats
Indu Pal Kaur
Favorite
Kawakami, Kohsaku

National Institute for Materials Science
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Kohsaku Kawakami
Favorite
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Kohsaku Kawakami
Favorite
(T1330-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Kohsaku Kawakami
Favorite
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Kohsaku Kawakami
Favorite
(W1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides III Thermodynamic Analysis on Higher-Order Structure of Oligonucleotides
Kohsaku Kawakami
Favorite
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Kohsaku Kawakami
Favorite
(W1230-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Kohsaku Kawakami
Favorite
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Kohsaku Kawakami
Favorite
(W1430-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides V Biological Function Analysis of Oligodeoxynucleotides
Kohsaku Kawakami
Favorite
Kawase, Naoki

Astellas Pharm Inc.
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Naoki Kawase
Favorite
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Naoki Kawase
Favorite
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Naoki Kawase
Favorite
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Naoki Kawase
Favorite
Kayoka, Kamba

Moderna Therapeutics
(T1530-02-06) Development of an Electrochemiluminescent Assay for the Detection of Anti-PEG IgE Antibodies in Human Serum
Kamba Kayoka
Favorite
Kazeroonian, Atefeh

Differentia Bio
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Atefeh Kazeroonian
Favorite
Kelly, Adrian

University of Bradford
(T1030-02-08) Single Cell Gel Electrophoresis to Detect Genotoxicity of Iminostilbene, a Process Induced Impurity of Carbamazepine
Adrian Kelly
Favorite
Kendle, Wesley

BioAgilytix Labs
(W1530-02-09) Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Wesley Kendle
Favorite
Kennedy, Derek

Ultragenyx Pharmaceuticals
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC^spf-ash Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Derek Kennedy
Favorite
Keve, Steve

Ultragenyx Pharmaceuticals
(W1430-02-10) Analysis of Anti-Drug Antibodies (ADA) in Multiple Animal Species from mRNA LNP Therapeutics Supporting Rare Diseases Demonstrated Low Immunogenicity of PEG-2000 by ECLA and ELISA Methodology
Steve Keve
Favorite
Keyhani, Anahita

Altasciences
(T1230-02-11) Sensitive Quantitation of Antisense Oligonucleotides Using Capitainer^® qDBS Microsampling Device Coupled with Hybridization LC-MS/MS
Anahita Keyhani
Favorite
Khanna, Pooja

Merck & Co., Inc.
(W1330-02-07) Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Pooja Khanna
Favorite
Khosraviani, Mehraban

Genentech, Inc.
(T1330-02-08) Production and Characterization of Critical Biotin and DIG Conjugated RESCA-Anti-CD8 VHH Reagents to Enable the Non-Clinical and Clinical Anti-Drug Antibody Assay Development
Mehraban Khosraviani
Favorite
Kiang, Patty

Cellentia, Inc.
(T1330-02-10) Novel Immunoassay Technology: Evaluating the PIXI Platform for Rapid Quantitation with Automation, Wide Dynamic Range, and Small Sample Volume Requirement
Patty Kiang
Favorite
Kim, Hyun-Jung

AstraZeneca
(T1130-02-06) Biodistribution Analysis of GPC-3 CAR-T Cells in NSG Mice by a Universal ddPCR Assay to Support an IND-Enabling Toxicity Study
Hyun-Jung Kim
Favorite
Kim, Inyong

Mayo Clinic
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Inyong Kim
Favorite
Kim, Jiwon

Mayo Clinic
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Jiwon Kim
Favorite
Kim, Michael

Genentech, Inc.
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Michael Kim
Favorite
Kim, Sang Yeop

Merck & Co., Inc.
(T1230-02-08) Quantitation of Soluble Tumor-Associated Antigens (sTAA) in Tumor Interstitial Fluid (TIF) Isolated from Frozen Solid Tumors
Sang Yeop Kim
Favorite
Kim, Sunjung

Ultragenyx Pharmaceuticals
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC^spf-ash Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Sunjung Kim
Favorite
Kinne, Adam

B2S Life Sciences
(W1430-02-06) Application of a Novel Affinity Purified Chicken IgY in an Immunoaffinity LC-MS/MS Assay for Rapid Quantitation of Monoclonal Antibody Therapeutics and ADCs in Nonclinical Species
Adam Kinne
Favorite
Klauss, Linda

Gyros Protein Technologies
(T1530-02-10) Development of a Generic, Automated, Microfluidic Human IgG-FcRn Affinity Assay In-Solution for Use in Antibody Engineering
Linda Klauss
Favorite
Koerber, James

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
James Koerber
Favorite
Kogaki, Takahiro

Daiichi Sankyo Co., Ltd.
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Takahiro Kogaki
Favorite
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Takahiro Kogaki
Favorite
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Takahiro Kogaki
Favorite
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Takahiro Kogaki
Favorite
Kommineni, Nagavendra

Rockefeller University
(W1330-01-02) Poloxamer 188 and Propylene Glycol Loaded with Novel Pyridine-Based 1,2,4-Triazolo-Tethered Indole Conjugate as Rectal Suppository to Treat Colorectal Cancer
Nagavendra Kommineni
Favorite
Komura, Fusae

Eisai Co., Ltd.
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Fusae Komura
Favorite
(T1330-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Fusae Komura
Favorite
Korde, Sachin A

University of Bradford
(T1030-02-08) Single Cell Gel Electrophoresis to Detect Genotoxicity of Iminostilbene, a Process Induced Impurity of Carbamazepine
Sachin A Korde
Favorite
Koscec, Mirna

Ultragenyx Pharmaceuticals
(W1430-02-10) Analysis of Anti-Drug Antibodies (ADA) in Multiple Animal Species from mRNA LNP Therapeutics Supporting Rare Diseases Demonstrated Low Immunogenicity of PEG-2000 by ECLA and ELISA Methodology
Mirna Koscec
Favorite
Kullmann, Aura

NeuroOne
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Aura Kullmann
Favorite
Kumar, Rajender

Post Graduate Institute of Medical Education and Research
(W1530-02-08) Non-invasive Molecular Imaging of V3 Receptors to Localize ACTH-Dependent Cushing's Syndrome and Precision Surgery of Corticotropinoma
Rajender Kumar
Favorite
L
Löthberg, Frida

Gyros Protein Technologies
(T1330-02-11) Oligonucleotide Dual Hybridization Assay Using Offline Pre-incubation followed by an Automated Microfluidic Method
Frida Löthberg
Favorite
(W1130-02-11) Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Frida Löthberg
Favorite
Lachacz, Eric

AstraZeneca
(T1130-02-06) Biodistribution Analysis of GPC-3 CAR-T Cells in NSG Mice by a Universal ddPCR Assay to Support an IND-Enabling Toxicity Study
Eric Lachacz
Favorite
Lakshminarasimhan, Maha

Merck Sharp & Dohme Corp.
(W1330-02-07) Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Maha Lakshminarasimhan
Favorite
Lee, Shin-Jae

University of Southern California
(W1230-01-03) Elastin-Like Polypeptide (ELP) Antibody Fusions Targeting IL-6: Pharmacology and Pharmacokinetics
Shin-Jae Lee
Favorite
Lee, Sun

Ultragenyx Pharmaceuticals
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC^spf-ash Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Sun Lee
Favorite
Lehmann, Michael

AstraZeneca
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Michael Lehmann
Favorite
Lelias, Sandra

EpiVax, Inc.
(W1130-02-09) Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
Sandra Lelias
Favorite
Li, Amy Hao

Genentech, Inc.
(T1330-02-09) Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Amy Hao Li
Favorite
Liao, Karen

Merck & Co., Inc.
(T1530-02-09) False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Karen Liao
Favorite
Li, Fengxia

Ultragenyx Pharmaceuticals
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC^spf-ash Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Fengxia Li
Favorite
Li, Junyi

Genentech, Inc.
(T1430-02-09) Bridging Bevacizumab PK from Adults to Pediatrics through PBPK Modeling
Junyi Li
Favorite
Lin, Alyse

Genentech, Inc.
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Alyse Lin
Favorite
Linh, Dinh Khanh

University of Cincinnati
(T1030-02-10) Synthesis a Cationic-Polymer Incorporating Carboxylesterase Active Ester for the Delivery of CRISPR/Cas9 to Ameliorate Hyperlipidemia
Dinh Khanh Linh
Favorite
(W1030-01-03) Oral Delivery of Remdesivir Analogues: Alternatives for Intravenous Remdesivir with Reduced Potential Drug-Drug Interactions
Dinh Khanh Linh
Favorite
Lin, Zhongping

Frontage Laboratories, Inc.
(W1530-02-11) Evaluation of API 7500 Integrated System with Microflow LC System M5 Using Sulfamethazine (SDX) Neat Solution
Zhongping Lin
Favorite
Lin, Yu-Jiun (Nate)

Merck & Co., Inc.
(T1130-02-10) A Novel Approach to Mechanical Characterization of Pharmaceutical Lyospheres
Yu-Jiun (Nate) Lin
Favorite
Liu, Bob

Genentech, Inc.
(T1330-02-06) Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Bob Liu
Favorite
Liu, Chang

Genentech, Inc.
(T1330-02-07) Optimizing and Validating an In Vitro Transcytosis Assay for Predicting Pharmacokinetics in Drug Discovery and Process Development
Chang Liu
Favorite
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Chang Liu
Favorite
Liu, Hui

AstraZeneca
(T1130-02-06) Biodistribution Analysis of GPC-3 CAR-T Cells in NSG Mice by a Universal ddPCR Assay to Support an IND-Enabling Toxicity Study
Hui Liu
Favorite
Liu, Luna

Genentech, Inc.
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Luna Liu
Favorite
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Luna Liu
Favorite
Liu, Stephanie

Genentech, Inc.
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Stephanie Liu
Favorite
Liu, Wei

Teva Pharmaceuticals, Inc.
(W1230-01-02) Impact of Amino Acids as Excipients in Biologic Drug Products Formulation Development
Wei Liu
Favorite
Liu, Wenyu

Genentech, Inc.
(T1330-02-06) Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Wenyu Liu
Favorite
Liu, Xiaoyan

Genentech, Inc.
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Xiaoyan Liu
Favorite
Li, Yihan

Abbvie
(T1430-02-10) A Novel In Vitro Serum Stability Assay for Antibody Therapeutics Incorporating Internal Standards
Yihan Li
Favorite
Lodaya, Rushit

GlaxoSmithKline plc
(W1330-01-05) Extrapolating the Use of Microfluidic Chips to Formulate Reproducible and Effective Nanoemulsions for Subunit Vaccines: A Paradigm Shift in Manufacturing Emulsion Adjuvants
Rushit Lodaya
Favorite
Lowes, Steve

Q Squared Solutions
(W1430-02-09) Exploring the Future Potentials of High-Resolution Mass Spectrometry for Regulated Bioanalysis
Steve Lowes
Favorite
Luo, Linlin

Merck & Co., Inc.
(T1530-02-09) False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Linlin Luo
Favorite
M
MacKay, J. Andrew

University of Southern California
(W1230-01-03) Elastin-Like Polypeptide (ELP) Antibody Fusions Targeting IL-6: Pharmacology and Pharmacokinetics
J. Andrew MacKay
Favorite
Maijorovaite, Zaneta

Teva Pharmaceuticals, Inc.
(W1230-01-02) Impact of Amino Acids as Excipients in Biologic Drug Products Formulation Development
Zaneta Maijorovaite
Favorite
Manandhar, Pragya

Teva Pharmaceuticals, Inc.
(W1230-01-02) Impact of Amino Acids as Excipients in Biologic Drug Products Formulation Development
Pragya Manandhar
Favorite
Mangadu, Ruban

Merck & Co., Inc.
(T1230-02-08) Quantitation of Soluble Tumor-Associated Antigens (sTAA) in Tumor Interstitial Fluid (TIF) Isolated from Frozen Solid Tumors
Ruban Mangadu
Favorite
Manikkath, Jyothsna

Manipal Academy of Higher Education
(T1230-01-04) Iontophoretic Transdermal Delivery of a Bioactive Molecule: Comparison of Nanoliposomal Platforms with Passive Delivery
Jyothsna Manikkath
Favorite
Mao, Yan

Boehringer-Ingelheim
(T1230-02-07) A Validated Immunocapture LC-MS/MS Hybrid Assay for the Quantitation of a Novel Multi-Domain Therapeutic Protein in Human Plasma with Clinical Sample Analysis
Yan Mao
Favorite
Marchand, Mathilde

Certara
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Mathilde Marchand
Favorite
Marchando, Sydney

Phosphorex
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Sydney Marchando
Favorite
Martin, William

EpiVax, Inc.
(T1130-02-11) Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
William Martin
Favorite
(W1130-02-09) Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
William Martin
Favorite
(W1230-02-11) Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
William Martin
Favorite
(W1530-02-10) An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)
William Martin
Favorite
Mattei, Aimee

EpiVax, Inc.
(T1130-02-11) Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Aimee Mattei
Favorite
(W1130-02-09) Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
Aimee Mattei
Favorite
(W1530-02-10) An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)
Aimee Mattei
Favorite
McAllister, Mitchell

EpiVax, Inc.
(W1230-02-11) Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
Mitchell McAllister
Favorite
McNeil, Mary

NeuroOne
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Mary McNeil
Favorite
Meissen, John K.

AstraZeneca
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
John K. Meissen
Favorite
Mejia Cardenas, Karina

BioAgilytix Labs
(W1530-02-09) Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Karina Mejia Cardenas
Favorite
Mekhssian, Kevork

Altasciences
(T1230-02-11) Sensitive Quantitation of Antisense Oligonucleotides Using Capitainer^® qDBS Microsampling Device Coupled with Hybridization LC-MS/MS
Kevork Mekhssian
Favorite
Melendez, Rachel

Genentech, Inc.
(T1330-02-06) Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Rachel Melendez
Favorite
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Rachel Melendez
Favorite
Meng, Shuxia

Genentech, Inc.
(T1330-02-07) Optimizing and Validating an In Vitro Transcytosis Assay for Predicting Pharmacokinetics in Drug Discovery and Process Development
Shuxia Meng
Favorite
Menon, Sreejit

Croda, Inc.
(T1330-01-05) Optimizing Lipid Nanoparticles (LNPs) Processing for siRNA Delivery by Microfluidics System
Sreejit Menon
Favorite
Milewski, Mikolaj

Merck & Co., Inc.
(T1230-01-01) Parallel-Competitive Absorption Metabolism Model for Calculation of Subcutaneous Bioavailability of Monoclonal Antibodies
Mikolaj Milewski
Favorite
Misra, Bishal

West Virginia University
(T1030-01-05) Flash Nanoprecipitation Permits Self-assembly of Ionizable Lipid Nanoparticles for Nucleic Acid Delivery
Bishal Misra
Favorite
(T1430-01-04) Ionizable Lipid Nanoparticles for Dual siRNA/Chemotherapy Delivery for B-cell ALL Treatment
Bishal Misra
Favorite
Mittal, Bhagwant

Post Graduate Institute of Medical Education and Research
(W1530-02-08) Non-invasive Molecular Imaging of V3 Receptors to Localize ACTH-Dependent Cushing's Syndrome and Precision Surgery of Corticotropinoma
Bhagwant Mittal
Favorite
Miura, Kanako

Daiichi Sankyo Co., Ltd.
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Kanako Miura
Favorite
(W1230-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Kanako Miura
Favorite
Miyahara, Yuya

Mitsubishi Tanabe Pharma Corporation
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Yuya Miyahara
Favorite
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Yuya Miyahara
Favorite
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Yuya Miyahara
Favorite
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Yuya Miyahara
Favorite
Miyajima, Makoto

Daiichi Sankyo Co., Ltd.
(W1230-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Makoto Miyajima
Favorite
Miyashita-Lin, Emily

Cellentia, Inc.
(W1430-02-08) In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Emily Miyashita-Lin
Favorite
Mizoguchi, Junichi

Eisai Co., Ltd.
(T1330-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Junichi Mizoguchi
Favorite
Moinuddin, Sakib Mohammad

California Northstate University
(W1030-01-04) Preparation and Scale-Up of Liposomal Amphotericin B Formulation and a Comparison with Commercially Available Counterpart, Ambisome®
Sakib Mohammad Moinuddin
Favorite
Moreno, Jonathan

Chapman University
(W1030-02-09) Design and Evaluation of a Cyclic Peptide-Epirubicin Conjugate to Enhance Anticancer Activity and Reduce Cardiac Toxicity
Jonathan Moreno
Favorite
Mosharraf, Mitra

Engimata
(T1330-01-04) Predicting the Aggregation Behavior of Liposomes Using Thermal Analysis
Mitra Mosharraf
Favorite
(W1430-01-05) Characterization of Protein Antigens in Liposomal Vaccines Using Differential Scanning Fluorimetry
Mitra Mosharraf
Favorite
Murai, Aliaa

Qatar University
(W1330-01-04) Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Aliaa Murai
Favorite
Murashov, Mikhail

Merck & Co., Inc.
(T1230-01-01) Parallel-Competitive Absorption Metabolism Model for Calculation of Subcutaneous Bioavailability of Monoclonal Antibodies
Mikhail Murashov
Favorite
Mutalik, Srinivas

Manipal College of Pharmaceutical Sciences
(T1230-01-04) Iontophoretic Transdermal Delivery of a Bioactive Molecule: Comparison of Nanoliposomal Platforms with Passive Delivery
Srinivas Mutalik
Favorite
N
Nandita, Eshani

SCIEX
(T1430-02-07) Analysis of Glucagon-Like Peptide-1 (GLP-1) Analog in Rat Plasma Using an LC-MS/MS Workflow
Eshani Nandita
Favorite
Narayanan, Padma

Wave Life Sciences
(W1230-02-06) Strategies for the Development and Characterization of Sensitive Anti-oligonucleotide Antibodies for Application in Anti-drug Antibody Assays
Padma Narayanan
Favorite
Nasar, Adam

Labcorp
(T1330-01-02) Formulation Development and Characterization of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine with a Toll-Like Receptor 7 Agonist
Adam Nasar
Favorite
(T1530-02-11) Formulation Development and Characterization of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine with CpG Oligonucleotide
Adam Nasar
Favorite
(W1230-01-05) Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Adam Nasar
Favorite
Nayar, Rajiv

HTD Biosystems Inc.
(T1330-01-04) Predicting the Aggregation Behavior of Liposomes Using Thermal Analysis
Rajiv Nayar
Favorite
(W1430-01-05) Characterization of Protein Antigens in Liposomal Vaccines Using Differential Scanning Fluorimetry
Rajiv Nayar
Favorite
Needham, Shane

Veloxity Labs
(W1430-02-06) Application of a Novel Affinity Purified Chicken IgY in an Immunoaffinity LC-MS/MS Assay for Rapid Quantitation of Monoclonal Antibody Therapeutics and ADCs in Nonclinical Species
Shane Needham
Favorite
Nejadnik, M. Reza

University of Iowa
(T1030-01-03) Stability of Therapeutic Monoclonal Antibodies during Infusion with Elastomeric Pumps Intended for Home-Based Therapy
M. Reza Nejadnik
Favorite
Ngo, Karen

Janssen Research & Development, LLC
(T1130-02-09) Evaluation of Sample Preparation Techniques for Protein Quantification
Karen Ngo
Favorite
Nguyen, Hiep

The Center for Innovation and Science
(T1430-01-02) Enhanced Transdermal Delivery of Anticancer Agent: A Comprehensive Study on Fractional Ablative Laser
Hiep Nguyen
Favorite
Nie, Haichen

Teva Pharmaceuticals, Inc.
(W1230-01-02) Impact of Amino Acids as Excipients in Biologic Drug Products Formulation Development
Haichen Nie
Favorite
Nijem, Ihsan

Genentech, Inc.
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Ihsan Nijem
Favorite
Nishi, Hirotaka

Daiichi Sankyo Co., Ltd.
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Hirotaka Nishi
Favorite
(W1230-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Hirotaka Nishi
Favorite
Njenga, Moses

Wave Life Sciences
(W1230-02-06) Strategies for the Development and Characterization of Sensitive Anti-oligonucleotide Antibodies for Application in Anti-drug Antibody Assays
Moses Njenga
Favorite
Norouzi, Masoud

University of Toronto
(W1030-02-06) Antibody Synthesis in Cell-Free for High-Throughput Production and Screening
Masoud Norouzi
Favorite
Nyholm, Karen

Waters Corporation
(W1330-02-10) Next-Generation Biocompatible HPLC System for Enhanced Analysis of Biotherapeutics
Karen Nyholm
Favorite
O
O'Hagan, Derek

GlaxoSmithKline plc
(W1330-01-05) Extrapolating the Use of Microfluidic Chips to Formulate Reproducible and Effective Nanoemulsions for Subunit Vaccines: A Paradigm Shift in Manufacturing Emulsion Adjuvants
Derek O'Hagan
Favorite
Ortega-Rodriguez, Uriel

US Food and Drug Administration
(W1030-02-07) Comparative Analyses of Thermal Stability Amplifying Peptide Dendrons and Polysorbates
Uriel Ortega-Rodriguez
Favorite
Oupicky, David

University of Nebraska Medical Center
(T1230-01-05) Development of Inhalable Polymeric Nanoemulsions for Delivery of Gene Silencing Therapeutics in Lung Tumors
David Oupicky
Favorite
P
Paco, Lorela

Merck & Co., Inc.
(T1230-02-08) Quantitation of Soluble Tumor-Associated Antigens (sTAA) in Tumor Interstitial Fluid (TIF) Isolated from Frozen Solid Tumors
Lorela Paco
Favorite
Pan, Cuiping

Greater Bay Area Institute of Precision Medicine
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Cuiping Pan
Favorite
Pandav, Kumud

Post Graduate Institute of Medical Education and Research
(W1530-02-08) Non-invasive Molecular Imaging of V3 Receptors to Localize ACTH-Dependent Cushing's Syndrome and Precision Surgery of Corticotropinoma
Kumud Pandav
Favorite
Pandey, Somit

Post Graduate Institute of Medical Education and Research
(W1530-02-08) Non-invasive Molecular Imaging of V3 Receptors to Localize ACTH-Dependent Cushing's Syndrome and Precision Surgery of Corticotropinoma
Somit Pandey
Favorite
Panfilov, Sabina

University of Toronto
(W1030-02-06) Antibody Synthesis in Cell-Free for High-Throughput Production and Screening
Sabina Panfilov
Favorite
Panja, Sudipta

University of Nebraska Medical Center
(T1230-01-05) Development of Inhalable Polymeric Nanoemulsions for Delivery of Gene Silencing Therapeutics in Lung Tumors
Sudipta Panja
Favorite
Paradkar, Anant

University of Bradford
(T1030-02-08) Single Cell Gel Electrophoresis to Detect Genotoxicity of Iminostilbene, a Process Induced Impurity of Carbamazepine
Anant Paradkar
Favorite
Parang, Keykavous

Chapman University
(W1030-02-09) Design and Evaluation of a Cyclic Peptide-Epirubicin Conjugate to Enhance Anticancer Activity and Reduce Cardiac Toxicity
Keykavous Parang
Favorite
Parmer, Elijah

B2S Life Sciences
(W1430-02-06) Application of a Novel Affinity Purified Chicken IgY in an Immunoaffinity LC-MS/MS Assay for Rapid Quantitation of Monoclonal Antibody Therapeutics and ADCs in Nonclinical Species
Elijah Parmer
Favorite
Patrick, Jeff

BioAgilytix Labs
(W1530-02-09) Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Jeff Patrick
Favorite
Pegram, Mark

Stanford University
(W1430-02-08) In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Mark Pegram
Favorite
Peng, Kate

Genentech, Inc.
(T1230-02-10) Development of a Highly Sensitive Immunoassay to Measure Circulating Levels of a Nanobody-Based Imaging Agent
Kate Peng
Favorite
(T1330-02-06) Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Kate Peng
Favorite
Pentz, William

West Virginia University
(T1430-01-04) Ionizable Lipid Nanoparticles for Dual siRNA/Chemotherapy Delivery for B-cell ALL Treatment
William Pentz
Favorite
Phan, Alvin

University of Southern California
(W1230-01-03) Elastin-Like Polypeptide (ELP) Antibody Fusions Targeting IL-6: Pharmacology and Pharmacokinetics
Alvin Phan
Favorite
Pillai-Kastoori, Lakshmi

BioAgilytix Labs
(W1530-02-09) Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Lakshmi Pillai-Kastoori
Favorite
Plomley, Jeff

Altasciences
(T1230-02-11) Sensitive Quantitation of Antisense Oligonucleotides Using Capitainer^® qDBS Microsampling Device Coupled with Hybridization LC-MS/MS
Jeff Plomley
Favorite
Poon, Kirsten

Ultragenyx Pharmaceuticals
(W1430-02-10) Analysis of Anti-Drug Antibodies (ADA) in Multiple Animal Species from mRNA LNP Therapeutics Supporting Rare Diseases Demonstrated Low Immunogenicity of PEG-2000 by ECLA and ELISA Methodology
Kirsten Poon
Favorite
Porto Cruz, Maria

NeuroOne
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Maria Porto Cruz
Favorite
Pritts, Jordan

US Food and Drug Administration
(W1030-02-07) Comparative Analyses of Thermal Stability Amplifying Peptide Dendrons and Polysorbates
Jordan Pritts
Favorite
Pushadapu, V V Siva Krishna

Vignan Pharmacy College
(W1330-01-02) Poloxamer 188 and Propylene Glycol Loaded with Novel Pyridine-Based 1,2,4-Triazolo-Tethered Indole Conjugate as Rectal Suppository to Treat Colorectal Cancer
V V Siva Krishna Pushadapu
Favorite
Putnam, Wendy

Ultragenyx Pharmaceuticals
(W1530-02-06) Age-Dependent Reduction in Hepatic Vector Genome Loss in Juvenile OTC^spf-ash Mice Following a Single Dose of DTX301 and Partial Compensation Achieved with a Higher Dose
Wendy Putnam
Favorite
Puttagunta, Srinivasa Babu

Vignan Pharmacy College
(W1330-01-02) Poloxamer 188 and Propylene Glycol Loaded with Novel Pyridine-Based 1,2,4-Triazolo-Tethered Indole Conjugate as Rectal Suppository to Treat Colorectal Cancer
Srinivasa Babu Puttagunta
Favorite
Q
Quan, Cynthia

Genentech, Inc.
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Cynthia Quan
Favorite
R
Radu, Maria

Merck & Co., Inc.
(W1330-02-11) One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Maria Radu
Favorite
Randolph, Theodore

University of Colorado Boulder
(T1330-01-03) Stain-Free Approach to Determine and Monitor Cell Heath Using Supervised and Unsupervised Image-Based Deep Learning
Theodore Randolph
Favorite
(W1030-02-11) Machine Learning Approaches to Analysis of Microscopy Images of Polysorbate Degradation Product Particles
Theodore Randolph
Favorite
(W1330-01-01) Stabilization of Viruses for Vaccines and Gene Therapy by Spray Drying and Lyophilization
Theodore Randolph
Favorite
Rao, V. Ashutosh

US Food and Drug Administration
(W1030-02-07) Comparative Analyses of Thermal Stability Amplifying Peptide Dendrons and Polysorbates
V. Ashutosh Rao
Favorite
Rathore, Anurag

Indian Institute of Technology
(W1030-02-07) Comparative Analyses of Thermal Stability Amplifying Peptide Dendrons and Polysorbates
Anurag Rathore
Favorite
Ren, Bailuo

Boehringer Ingelheim
(T1230-02-07) A Validated Immunocapture LC-MS/MS Hybrid Assay for the Quantitation of a Novel Multi-Domain Therapeutic Protein in Human Plasma with Clinical Sample Analysis
Bailuo Ren
Favorite
Robbie, Joanna

BioAgilytix Labs
(W1530-02-09) Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Joanna Robbie
Favorite
Roberts, Brian

EpiVax, Inc.
(W1130-02-09) Immunogenicity Risk Assessment of Salmon Calcitonin Peptide Impurities Using In Silico and In Vitro Methods
Brian Roberts
Favorite
(W1230-02-11) Comprehensive Assessment of Immunogenicity Risk of Host Cell Proteins in Biologics and Vaccines Using In Silico and In Vitro Methods
Brian Roberts
Favorite
Rodó, Jordi

Svar Life Science AB
(W1130-02-11) Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Jordi Rodó
Favorite
Rodriguez, Alejandro

Genentech, Inc.
(T1330-02-09) Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Alejandro Rodriguez
Favorite
(W1130-02-10) Choosing the Right Bioanalytical Platform to Accommodate a Biotherapeutic Pharmacokinetic Measurement in Serum and CSF: A Case Study
Alejandro Rodriguez
Favorite
Roos, David

Boehringer Ingelheim
(T1230-02-07) A Validated Immunocapture LC-MS/MS Hybrid Assay for the Quantitation of a Novel Multi-Domain Therapeutic Protein in Human Plasma with Clinical Sample Analysis
David Roos
Favorite
Rosa, Dave

NeuroOne
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Dave Rosa
Favorite
Rosenbaum, Anton

AstraZeneca
(T1130-02-06) Biodistribution Analysis of GPC-3 CAR-T Cells in NSG Mice by a Universal ddPCR Assay to Support an IND-Enabling Toxicity Study
Anton Rosenbaum
Favorite
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Anton Rosenbaum
Favorite
Rosenberg, Amy

EpiVax, Inc.
(T1130-02-11) Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Amy Rosenberg
Favorite
(W1530-02-10) An “I” (Immunogenicity Risk Assessment) for an Eye (Ophthalmology Biologics)
Amy Rosenberg
Favorite
Rutz, Sascha

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Sascha Rutz
Favorite
S
Saddekar, Shraddha

Genentech, Inc.
(T1430-02-08) Leveraging Buprenorphine as a Tool Molecule to Develop a Novel PBPK Model Accounting for Intestinal Lymphatic Absorption
Shraddha Saddekar
Favorite
Sarkar, Tanoy

California Northstate University
(W1030-01-04) Preparation and Scale-Up of Liposomal Amphotericin B Formulation and a Comparison with Commercially Available Counterpart, Ambisome®
Tanoy Sarkar
Favorite
Sarvaiya, Hetal

Abbvie
(T1430-02-10) A Novel In Vitro Serum Stability Assay for Antibody Therapeutics Incorporating Internal Standards
Hetal Sarvaiya
Favorite
Sastry, Skanda

Genentech, Inc.
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Skanda Sastry
Favorite
Sauve, Zacharie

Certara
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Zacharie Sauve
Favorite
Scapin, Giovana

Nanoimaging Services
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Giovana Scapin
Favorite
Schartner, Jill

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Jill Schartner
Favorite
Schimmel, Margaret

University of California Santa Barbara
(W1430-02-07) Novel Use of Recombinant Dimeric IgA Monoclonal Antibodies as Cyst-Targeted Therapeutics in Polycystic Kidney Disease
Margaret Schimmel
Favorite
Schlesinger, Erica

Seran Biosciences
(W1430-01-02) High Concentration Protein Suspensions: A Case Study for Subcutaneous Delivery of Bevacizumab
Erica Schlesinger
Favorite
Schneider, Thomas

BioAgilytix Labs
(W1230-02-10) Qualification of a 48-plex Cytokine Olink Panel to Support Rare Disease and Pediatric Clinical Studies
Thomas Schneider
Favorite
Schwartz, Daniel

University of Colorado Boulder
(W1330-01-01) Stabilization of Viruses for Vaccines and Gene Therapy by Spray Drying and Lyophilization
Daniel Schwartz
Favorite
Selen, Ebru

SCIEX
(T1430-02-07) Analysis of Glucagon-Like Peptide-1 (GLP-1) Analog in Rat Plasma Using an LC-MS/MS Workflow
Ebru Selen
Favorite
Sellin, Mikael

Uppsala University
(W1030-02-08) Optimization of Artificial Colonic Mucus for Drug Diffusion Study
Mikael Sellin
Favorite
Senda, Masaaki

Sawai Pharmaceutical Co., Ltd.
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Masaaki Senda
Favorite
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Masaaki Senda
Favorite
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Masaaki Senda
Favorite
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Masaaki Senda
Favorite
Seshadri, Soorya

EpiVax, Inc.
(T1130-02-11) Rapid and Predictive Immunogenicity Risk Assessments Using In Silico Methods
Soorya Seshadri
Favorite
Shearer-Kang, Esther

Genentech, Inc.
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Esther Shearer-Kang
Favorite
Shen, Ben-Quan

Genentech, Inc.
(T1530-02-07) Integrated HypoSkin® Model and PBPK Modeling as a Bioavailability Predicting Tool for Subcutaneous Delivery of Protein Therapeutics
Ben-Quan Shen
Favorite
Sheng, Xinyi

Georgia Institute of Technology
(W1330-01-03) Deciphering the Role of Hydrogel Network Topology in Programmably Degradable Hydrogels
Xinyi Sheng
Favorite
Shen, Yue

University of Cincinnati
(W1030-01-03) Oral Delivery of Remdesivir Analogues: Alternatives for Intravenous Remdesivir with Reduced Potential Drug-Drug Interactions
Yue Shen
Favorite
Shih, Shian-Jiun

Cellentia, Inc.
(T1330-02-10) Novel Immunoassay Technology: Evaluating the PIXI Platform for Rapid Quantitation with Automation, Wide Dynamic Range, and Small Sample Volume Requirement
Shian-Jiun Shih
Favorite
(W1430-02-08) In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Shian-Jiun Shih
Favorite
Shim, Jeongsup

Genentech, Inc.
(T1330-02-09) Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Jeongsup Shim
Favorite
Shivva, Vittal

Genentech, Inc.
(T1530-02-07) Integrated HypoSkin® Model and PBPK Modeling as a Bioavailability Predicting Tool for Subcutaneous Delivery of Protein Therapeutics
Vittal Shivva
Favorite
Shi, Wenting

Georgia Institute of Technology
(W1330-01-03) Deciphering the Role of Hydrogel Network Topology in Programmably Degradable Hydrogels
Wenting Shi
Favorite
Shukla, Jaya

Post Graduate Institute of Medical Education and Research
(W1530-02-08) Non-invasive Molecular Imaging of V3 Receptors to Localize ACTH-Dependent Cushing's Syndrome and Precision Surgery of Corticotropinoma
Jaya Shukla
Favorite
Siddhanta, Kasturi

University of Nebraska Medical Center
(T1230-01-05) Development of Inhalable Polymeric Nanoemulsions for Delivery of Gene Silencing Therapeutics in Lung Tumors
Kasturi Siddhanta
Favorite
Siguenza, Patricia

Genentech, Inc.
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Patricia Siguenza
Favorite
Singh, Gurpal

Panjab University
(W1230-02-07) Docetaxel and QDs Based Nano Lipidic Theragnostic System for Cure and Real-Time Monitoring of Breast Cancer: Efficacy and Safety Studies in Rats
Gurpal Singh
Favorite
Singh, Jasmine

Gyros Protein Technologies
(T1330-02-11) Oligonucleotide Dual Hybridization Assay Using Offline Pre-incubation followed by an Automated Microfluidic Method
Jasmine Singh
Favorite
(T1530-02-10) Development of a Generic, Automated, Microfluidic Human IgG-FcRn Affinity Assay In-Solution for Use in Antibody Engineering
Jasmine Singh
Favorite
(W1130-02-11) Comparison of a Microfluidic Generic Total Antibody (TAb) Assay with Independent Neutralizing Antibody (NAb) and TAb Assays for the Detection of Pre-existing Antibodies against AAV Vectors
Jasmine Singh
Favorite
Singh, Joga

Panjab University
(W1230-02-07) Docetaxel and QDs Based Nano Lipidic Theragnostic System for Cure and Real-Time Monitoring of Breast Cancer: Efficacy and Safety Studies in Rats
Joga Singh
Favorite
Sinko, Balint

Pion Inc.
(T1030-01-02) Demonstrating the Excipient Effect In Vitro for Pre-clinical Formulation Analysis
Balint Sinko
Favorite
Siradze, Ketevan

Genentech, Inc.
(T1330-02-09) Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Ketevan Siradze
Favorite
Somaida, Ahmed

Philipps University of Marburg
(T1130-02-08) Intestinal Organoid as a Predictive Model for the Assessment of Nano-Drug Delivery Systems
Ahmed Somaida
Favorite
Sotomayor Albino, Anais

BioAgilytix Labs
(W1530-02-09) Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Anais Sotomayor Albino
Favorite
Sperinde, Gizette

Genentech, Inc.
(T1330-02-09) Gyrolab Generic Anti-drug Antibody Assay Streamlines Preclinical Immunogenicity Assessment
Gizette Sperinde
Favorite
(W1130-02-10) Choosing the Right Bioanalytical Platform to Accommodate a Biotherapeutic Pharmacokinetic Measurement in Serum and CSF: A Case Study
Gizette Sperinde
Favorite
Spiciarich, David R.

AstraZeneca
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
David R. Spiciarich
Favorite
Spinosa, Phillip

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Phillip Spinosa
Favorite
Spytko, Adriane

Q Squared Solutions
(W1430-02-09) Exploring the Future Potentials of High-Resolution Mass Spectrometry for Regulated Bioanalysis
Adriane Spytko
Favorite
Stachura, Nina

Merck & Co., Inc.
(W1330-02-11) One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Nina Stachura
Favorite
Stefanich, Eric

Genentech, Inc.
(T1430-02-08) Leveraging Buprenorphine as a Tool Molecule to Develop a Novel PBPK Model Accounting for Intestinal Lymphatic Absorption
Eric Stefanich
Favorite
Stevenson, Joseph

Merck Sharp & Dohme Corp.
(W1330-02-07) Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Joseph Stevenson
Favorite
Storey, Kristine

Merck & Co., Inc.
(T1530-02-09) False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Kristine Storey
Favorite
Subramanian, Kalyanasundaram

Differentia Bio
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Kalyanasundaram Subramanian
Favorite
Sugano, Yukihito

Astellas Pharma Inc.
(T1330-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Yukihito Sugano
Favorite
(W1230-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Yukihito Sugano
Favorite
Sule, Olagoke

Genentech, Inc.
(T1430-02-09) Bridging Bevacizumab PK from Adults to Pediatrics through PBPK Modeling
Olagoke Sule
Favorite
Sun, Di

AliveX Biotech
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Di Sun
Favorite
Sun, Li

Merck Sharp & Dohme Corp.
(W1330-02-07) Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Li Sun
Favorite
Sun, Ruimin

AliveX Biotech
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Ruimin Sun
Favorite
Surface, Morgan

West Virginia University
(T1430-01-04) Ionizable Lipid Nanoparticles for Dual siRNA/Chemotherapy Delivery for B-cell ALL Treatment
Morgan Surface
Favorite
Swanson, Steven

Genentech, Inc.
(T1330-02-07) Optimizing and Validating an In Vitro Transcytosis Assay for Predicting Pharmacokinetics in Drug Discovery and Process Development
Steven Swanson
Favorite
T
Tabata, Takahiro

Sawai Pharmaceutical Co., Ltd.
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Takahiro Tabata
Favorite
Taherian, Elham

University of Iowa
(T1030-01-03) Stability of Therapeutic Monoclonal Antibodies during Infusion with Elastomeric Pumps Intended for Home-Based Therapy
Elham Taherian
Favorite
Takeuchi, Shoko

Takeda Pharnaceutical Company
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Shoko Takeuchi
Favorite
Tang, Xiaonan

Frontage Laboratories, Inc.
(W1530-02-11) Evaluation of API 7500 Integrated System with Microflow LC System M5 Using Sulfamethazine (SDX) Neat Solution
Xiaonan Tang
Favorite
Tanimoto, Masahiko

Mitsubishi Tanabe Pharma Corporation
(W1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides III Thermodynamic Analysis on Higher-Order Structure of Oligonucleotides
Masahiko Tanimoto
Favorite
Tao, Xun

Genentech, Inc.
(T1430-02-08) Leveraging Buprenorphine as a Tool Molecule to Develop a Novel PBPK Model Accounting for Intestinal Lymphatic Absorption
Xun Tao
Favorite
(T1530-02-07) Integrated HypoSkin® Model and PBPK Modeling as a Bioavailability Predicting Tool for Subcutaneous Delivery of Protein Therapeutics
Xun Tao
Favorite
Teleki, Alexandra

Uppsala University
(W1030-02-08) Optimization of Artificial Colonic Mucus for Drug Diffusion Study
Alexandra Teleki
Favorite
Terrillon, Sonia

AstraZeneca
(T1130-02-06) Biodistribution Analysis of GPC-3 CAR-T Cells in NSG Mice by a Universal ddPCR Assay to Support an IND-Enabling Toxicity Study
Sonia Terrillon
Favorite
Thite, Nidhi

University of Colorado Boulder
(T1330-01-03) Stain-Free Approach to Determine and Monitor Cell Heath Using Supervised and Unsupervised Image-Based Deep Learning
Nidhi Thite
Favorite
Tian, Xuefei

Genentech, Inc.
(T1330-02-07) Optimizing and Validating an In Vitro Transcytosis Assay for Predicting Pharmacokinetics in Drug Discovery and Process Development
Xuefei Tian
Favorite
Tia, Sameul

Correlia
(T1330-02-10) Novel Immunoassay Technology: Evaluating the PIXI Platform for Rapid Quantitation with Automation, Wide Dynamic Range, and Small Sample Volume Requirement
Sameul Tia
Favorite
Tiwari, Rakesh

Western University of Health Sciences
(W1030-02-09) Design and Evaluation of a Cyclic Peptide-Epirubicin Conjugate to Enhance Anticancer Activity and Reduce Cardiac Toxicity
Rakesh Tiwari
Favorite
Tjakra, Marco

Uppsala University
(W1030-02-08) Optimization of Artificial Colonic Mucus for Drug Diffusion Study
Marco Tjakra
Favorite
Tomeh, Anas

LabCorp
(T1330-01-02) Formulation Development and Characterization of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine with a Toll-Like Receptor 7 Agonist
Anas Tomeh
Favorite
(T1530-02-11) Formulation Development and Characterization of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine with CpG Oligonucleotide
Anas Tomeh
Favorite
(W1230-01-05) Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Anas Tomeh
Favorite
Tomioka, Ryota

Shionogi & Co., Ltd.
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Ryota Tomioka
Favorite
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Ryota Tomioka
Favorite
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Ryota Tomioka
Favorite
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Ryota Tomioka
Favorite
Tortoles, Daphne

NanoImaging Services
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Daphne Tortoles
Favorite
Tran, Vy

Genentech, Inc.
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Vy Tran
Favorite
Trujillo, Adriana

NanoImaging Services
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Adriana Trujillo
Favorite
Tsutsumi, Shiho

Eisai Co., Ltd.
(T1330-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Shiho Tsutsumi
Favorite
Tuberty-Vaughan, Emma

AstraZeneca
(T1330-01-03) Stain-Free Approach to Determine and Monitor Cell Heath Using Supervised and Unsupervised Image-Based Deep Learning
Emma Tuberty-Vaughan
Favorite
V
Vazvaei-Smith, Faye

Merck & Co., Inc.
(T1530-02-09) False Positive or Not? – Assessing Potential Interference of Soluble Target to ADA Detection for a Clinical Stage Program
Faye Vazvaei-Smith
Favorite
Venet, Joris

Gyros Protein Technologies
(T1330-02-11) Oligonucleotide Dual Hybridization Assay Using Offline Pre-incubation followed by an Automated Microfluidic Method
Joris Venet
Favorite
Verch, Thorsten

Merck & Co., Inc.
(W1330-02-11) One Drop of Blood, Multiple Sets of Data --- Establishing A Common Protocol for Serotype Specific IGG Concentration Testing Using Mitra® VAMS Dry Blood Samples to Support Vaccine Clinical Studies
Thorsten Verch
Favorite
Villafeurte-Vega, Rosendo

University of Michigan
(T1430-02-10) A Novel In Vitro Serum Stability Assay for Antibody Therapeutics Incorporating Internal Standards
Rosendo Villafeurte-Vega
Favorite
Villamagna, Ian

Phosphorex
(W1330-02-09) Using Cryo-TEM to Characterize Structural Details of LNPs during Manufacturing
Ian Villamagna
Favorite
Vlasak, Josef

Merck & Co., Inc.
(T1030-02-11) The Importance of Orthogonal Methods for the Determination of the Size Distribution of Lipid Nanoparticles
Josef Vlasak
Favorite
Vomero, Maria

NeuroOne
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Maria Vomero
Favorite
W
Walia, Rama

Post Graduate Institute of Medical Education and Research
(W1530-02-08) Non-invasive Molecular Imaging of V3 Receptors to Localize ACTH-Dependent Cushing's Syndrome and Precision Surgery of Corticotropinoma
Rama Walia
Favorite
Wallace, Nicole

AstraZeneca
(T1330-01-03) Stain-Free Approach to Determine and Monitor Cell Heath Using Supervised and Unsupervised Image-Based Deep Learning
Nicole Wallace
Favorite
Wang, Bei

Genentech, Inc.
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Bei Wang
Favorite
Wang, Hongzhi

Genentech, Inc.
(T1530-02-07) Integrated HypoSkin® Model and PBPK Modeling as a Bioavailability Predicting Tool for Subcutaneous Delivery of Protein Therapeutics
Hongzhi Wang
Favorite
Wang, Xiangdan

Biopharmaceutical Research Inc.
(T1330-02-08) Production and Characterization of Critical Biotin and DIG Conjugated RESCA-Anti-CD8 VHH Reagents to Enable the Non-Clinical and Clinical Anti-Drug Antibody Assay Development
Xiangdan Wang
Favorite
Watkinson, Allan

LabCorp
(T1330-01-02) Formulation Development and Characterization of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine with a Toll-Like Receptor 7 Agonist
Allan Watkinson
Favorite
(T1530-02-11) Formulation Development and Characterization of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine with CpG Oligonucleotide
Allan Watkinson
Favorite
(W1230-01-05) Development of a Marburg Self-amplifying mRNA-Lipid Nanoparticle Vaccine: Differential Effects When Co-formulated with Toll Receptor Agonists
Allan Watkinson
Favorite
Weaver, Jessica

BioAgilytix Labs
(W1530-02-09) Development of Non-Cell Based Potency Assays for Bispecific Antibodies
Jessica Weaver
Favorite
Webb Vargas, Yenny

Genentech, Inc.
(T1330-02-07) Optimizing and Validating an In Vitro Transcytosis Assay for Predicting Pharmacokinetics in Drug Discovery and Process Development
Yenny Webb Vargas
Favorite
Weimbs, Thomas

University of California Santa Barbara
(W1430-02-07) Novel Use of Recombinant Dimeric IgA Monoclonal Antibodies as Cyst-Targeted Therapeutics in Polycystic Kidney Disease
Thomas Weimbs
Favorite
Wen, Shirley

AliveX Biotech
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Shirley Wen
Favorite
Wilcox, Paige

AstraZeneca
(T1330-01-03) Stain-Free Approach to Determine and Monitor Cell Heath Using Supervised and Unsupervised Image-Based Deep Learning
Paige Wilcox
Favorite
Woon, Nicholas

Genentech, Inc.
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Nicholas Woon
Favorite
Worrell, Gregory

Mayo Clinic
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Gregory Worrell
Favorite
Wu, Benjamin

Genentech, Inc.
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
Benjamin Wu
Favorite
X
Xie, Qing

Biopharmaceutical Research Inc.
(T1330-02-08) Production and Characterization of Critical Biotin and DIG Conjugated RESCA-Anti-CD8 VHH Reagents to Enable the Non-Clinical and Clinical Anti-Drug Antibody Assay Development
Qing Xie
Favorite
Xu, Keyang

Genentech, Inc.
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Keyang Xu
Favorite
(T1530-02-08) Cross Validation of Pharmacokinetic Assays: Experimental and Statistical Design
Keyang Xu
Favorite
Xu, Weifeng

Merck Sharp & Dohme Corp.
(W1330-02-07) Enhancing Antibody Detection for PABAD-Based Neutralizing Antibody Detection and Validation
Weifeng Xu
Favorite
Y
Yamaguchi, Katsutoshi

Astellas Pharma Inc.
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Katsutoshi Yamaguchi
Favorite
(T1330-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Katsutoshi Yamaguchi
Favorite
(W1230-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Katsutoshi Yamaguchi
Favorite
Yamazaki, Tomohiko

National Institute for Materials Science
(T1030-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides
Tomohiko Yamazaki
Favorite
(W1430-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides V Biological Function Analysis of Oligodeoxynucleotides
Tomohiko Yamazaki
Favorite
Yan, Bingfang

University of Cincinnati
(T1030-02-10) Synthesis a Cationic-Polymer Incorporating Carboxylesterase Active Ester for the Delivery of CRISPR/Cas9 to Ameliorate Hyperlipidemia
Bingfang Yan
Favorite
(W1030-01-03) Oral Delivery of Remdesivir Analogues: Alternatives for Intravenous Remdesivir with Reduced Potential Drug-Drug Interactions
Bingfang Yan
Favorite
Yang, Liu

AstraZeneca
(W1230-02-09) LC-MS FFPE Tissue Analysis Across Multiple Murine Tissues Supports Mouse Relevance for On-Target/Off-Tumor Toxicity Assessment for Anti-STEAP2 CAR-T Therapeutic Development
Liu Yang
Favorite
Yang, Yi

Genentech, Inc.
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Yi Yang
Favorite
Ye, Wei

AliveX Biotech
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Wei Ye
Favorite
Ying, Xi

Georgia Institute of Technology
(W1330-01-03) Deciphering the Role of Hydrogel Network Topology in Programmably Degradable Hydrogels
Xi Ying
Favorite
Yin, Zhaojun

Genentech, Inc.
(T1330-02-06) Utilizing a Bead-Based Sample Pretreatment to Overcome Drug Interference in Developing a Ligand Binding Neutralizing Antibody Assay
Zhaojun Yin
Favorite
Yoshida, Maki

Chugai Pharmaceutical Co., Ltd.
(T1230-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Overview
Maki Yoshida
Favorite
(T1430-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) C-terminal Lys Clipping
Maki Yoshida
Favorite
(W1130-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (2) Oxidation
Maki Yoshida
Favorite
(W1330-02-06) Interlaboratory Study of Multi-Attribute Method (MAM) for Antibody Therapeutics – Post-Translational Modification (1) Deamidation
Maki Yoshida
Favorite
Yoshimura, Seiji

Astellas Pharma Inc.
(T1330-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides II Circular Dichroism Spectroscopy and Nuclear Magnetic Resonance Analysis for Determining Higher-Order Structure
Seiji Yoshimura
Favorite
(W1230-01-01) Development of Physicochemical Profiling Platform for Therapeutic Oligonucleotides IV Evaluation of Compactness of Oligonucleotides for Determining Their Higher-Order Structure
Seiji Yoshimura
Favorite
Younes, Husam

Qatar University
(W1330-01-04) Prolonged Ocular Delivery of Sunitinib from Poly (diol-tricarballylate) Injectable Biodegradable Elastomeric Tiny Implant for Diabetic Retinopathy Treatment
Husam Younes
Favorite
Yu, Shang-Fan

Genentech, Inc.
(T1030-02-09) Evaluating the Effects of Differently Charged Linker-Drugs on Pharmacokinetics and Tissue Distribution of Antibody Drug Conjugates
Shang-Fan Yu
Favorite
Z
Zanghi, James

Genentech, Inc.
(T1230-02-09) Population Pharmacokinetics and Exposure-Efficacy and -Safety Analyses of Atezolizumab for Subcutaneous Injection in Patients with Locally Advanced or Metastatic Non-small Cell Lung Cancer
James Zanghi
Favorite
Zanghi, Jim

Genentech, Inc.
(T1430-01-03) Val-His-Ser (VHS) N-terminal Leader Sequence and Implications for mAb Subcutaneous Pharmacokinetics
Jim Zanghi
Favorite
Zepeda, Guadalupe

NeuroOne
(W1430-01-04) Innovative Device for Concomitant Therapeutic Compound Delivery into the Brain and Neural Recordings - Feasibility Bench and In Vivo Studies
Guadalupe Zepeda
Favorite
Zhang, Pingping

Cellentia, Inc.
(T1330-02-10) Novel Immunoassay Technology: Evaluating the PIXI Platform for Rapid Quantitation with Automation, Wide Dynamic Range, and Small Sample Volume Requirement
Pingping Zhang
Favorite
(W1430-02-08) In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Pingping Zhang
Favorite
Zhang, Ruobo

Cellentia, Inc.
(W1430-02-08) In Vitro Method Using Circulating Tumor Cells-Derived Organoids from Patients with Solid Tumors to Transform Oncology Drug Development
Ruobo Zhang
Favorite
Zhao, Harry

Frontage Laboratories, Inc.
(W1530-02-11) Evaluation of API 7500 Integrated System with Microflow LC System M5 Using Sulfamethazine (SDX) Neat Solution
Harry Zhao
Favorite
Zhao, Song

Frontage Laboratories, Inc.
(W1530-02-11) Evaluation of API 7500 Integrated System with Microflow LC System M5 Using Sulfamethazine (SDX) Neat Solution
Song Zhao
Favorite
Zhao, Wanbing

AliveX Biotech
(T1030-02-06) A Mechanistic Model of IgG4-RD Identifies High-Potential Therapy Targets
Wanbing Zhao
Favorite
Zhong, Yu

Genentech, Inc.
(T1130-02-07) Anti-CCR8 Mediated Depletion of Tumor-Infiltrating Regulatory T Cells: Preclinical PK/PD and Translational Strategy in Support of Clinical Development for Solid Tumor Indications
Yu Zhong
Favorite